|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
168.72 Million
|
|
CAGR (2025-2030)
|
5.78%
|
|
Fastest Growing Segment
|
Monolayer
Cell-sheet
|
|
Largest Market
|
China
|
|
Market Size (2030)
|
USD 233.71 Million
|
Market Overview
Asia Pacific Cell Sheet-based Gene
Therapy Market was valued at USD 168.72 Million in 2024 and is expected to
reach USD 233.71 Million by 2030 with a CAGR of 5.78%. This growth is being
driven by a combination of factors, including increasing investments in
research and development, the rising incidence of chronic and degenerative
diseases, and continuous advancements in tissue engineering technologies.
Countries such as Japan, South Korea, China, and Australia are emerging as key
players in both clinical and commercial applications of cell sheet-based gene
therapies.
One of the primary drivers of market
expansion is the region's growing healthcare expenditure. Governments and
private sectors are allocating substantial resources toward the development and
adoption of innovative treatments for complex conditions such as cancer,
cardiovascular diseases, and age-related disorders. Despite the positive outlook,
the Asia-Pacific market faces several challenges. These include high costs
associated with the production and scale-up of cell sheet-based therapies,
limited standardization in manufacturing processes, and the complexities of
navigating differing regulatory requirements across multiple jurisdictions.
Key Market Drivers
Growth
in Healthcare Industry
The rapid expansion of the healthcare
industry across the Asia Pacific region is emerging as a key driver for the
cell sheet-based gene therapy market. Asia is firmly establishing itself
as a global economic powerhouse, with its healthcare market poised for
unprecedented growth. Forecasted to reach approximately USD 5 trillion by 2030,
the region is expected to drive 40% of global healthcare expansion, propelled
by key demographic shifts. One
of the most significant contributors to this growth is the increasing demand
for personalized and regenerative medicine. As populations age and the
prevalence of chronic and degenerative diseases rises, healthcare systems are
shifting toward more innovative treatment modalities. Cell sheet-based gene
therapy, which offers targeted and minimally invasive therapeutic approaches,
aligns well with these evolving medical needs.
Moreover, advancements in biotechnology,
growing adoption of stem cell research, and supportive regulatory frameworks
are further accelerating the integration of gene therapies into mainstream
healthcare services. For instance, countries such as Japan have introduced
expedited approval processes for regenerative medicines, creating a favorable
environment for clinical trials and commercialization. India is advancing
stem cell research by focusing on both basic and translational studies. The
evolving strategy includes establishing Centers of Excellence, creating a
virtual research network, generating human embryonic stem cell lines, and
developing talent through training and international fellowships.
Surge
in Technological Advancements
The Asia Pacific region is witnessing a
transformative surge in technological innovations, significantly propelling the
growth of the cell sheet-based gene therapy market. This cutting-edge
therapeutic approach, which leverages the power of gene modification within
cultured cell sheets, is gaining momentum due to rapid progress in
bioengineering, regenerative medicine, and cellular manufacturing technologies.
Key advancements such as the development
of scaffold-free cell sheet engineering, improved gene editing tools like
CRISPR-Cas9, and automation in cell culture techniques have enhanced the
safety, efficacy, and scalability of cell sheet-based therapies. In 2024,
Scientists at the CSIR-Institute of Genomics and Integrative Biology, New
Delhi, have developed an advanced genome-editing system that offers greater
precision and efficiency compared to existing CRISPR-based technologies. These
technologies are not only improving clinical outcomes but also streamlining
production processes, reducing costs, and facilitating broader clinical
adoption.
Download Free Sample Report
Key Market Challenges
High
Production & Operational Costs
One of the foremost challenges facing
the Asia-Pacific cell sheet-based gene therapy market is the high production
and operational costs associated with these advanced therapies. The
manufacturing of cell sheet-based gene therapies involves complex, multi-step
processes that require specialized facilities, sophisticated equipment, and
highly skilled personnel. These factors collectively drive up the cost of
production, making it difficult for companies to achieve economies of scale or
offer competitive pricing.
Furthermore, maintaining stringent
quality control and regulatory compliance throughout the production cycle adds
additional layers of operational expense. The need for cleanroom environments,
aseptic processing, and continuous monitoring to ensure product consistency and
safety further inflates costs. In a region as diverse as Asia-Pacific, with
varying infrastructure capabilities and regulatory requirements, these
operational challenges are compounded.
Key Market Trends
Rising
Prevalence of Chronic and Genetic Diseases
A notable trend influencing the Asia
Pacific cell sheet-based gene therapy market is the rising prevalence of
chronic and genetic diseases across the region. Chronic diseases
represent a significant share of mortality in the South-East Asia Region,
varying from 34% in Timor-Leste to 79% in the Maldives. Driven by an
epidemiological transition towards noncommunicable diseases, the prevalence and
impact of chronic conditions continue to rise steadily. With rapid urbanization,
lifestyle changes, and an aging population, the incidence of conditions such as
cancer, cardiovascular diseases, diabetes, and hereditary disorders has been
steadily increasing. This surge in chronic and genetic ailments is driving
demand for innovative and effective treatment solutions.
Cell sheet-based gene therapy presents a
promising approach for addressing these complex diseases by enabling targeted,
regenerative treatment that can potentially correct genetic abnormalities and
restore damaged tissues. The technology’s ability to offer personalized and
minimally invasive therapies is particularly appealing in managing conditions
that have limited treatment options or require long-term care.
Segmental Insights
Sheet
Type Insights
Based on Sheet Type, Monolayer
Cell-sheet have emerged as the fastest growing segment in the Asia Pacific Cell
Sheet-based Gene Therapy Market in 2024. This segment benefits from streamlined
production processes, reduced complexity, and lower costs, making it highly
attractive for both manufacturers and healthcare providers. Moreover, monolayer
cell-sheets facilitate improved oxygen and nutrient diffusion, resulting in
better cell survival rates and enhanced regenerative outcomes.
Application
Insights
Based on Application, Oncology have
emerged as the fastest growing segment in the Asia Pacific Cell Sheet-based
Gene Therapy Market during the forecast period. The rising incidence of cancer
across the region, fueled by demographic shifts and changing lifestyles, has
created a substantial patient population in need of more effective treatments.
Traditional cancer therapies, while widely used, often come with limitations
such as severe side effects and variable efficacy. Cell sheet-based gene
therapies offer a promising alternative by providing targeted, innovative
solutions that address these gaps in treatment.
Download Free Sample Report
Country Insights
Based on Country, China have emerged as
the dominating country in the Asia Pacific Cell Sheet-based Gene Therapy Market
in 2024. The country’s leadership in clinical trial activity demonstrates its
strong commitment to advancing innovative therapies and accelerating their
development. This momentum is supported by a regulatory environment that has
become increasingly conducive to biotech innovation, featuring streamlined
approval processes and reforms designed to facilitate quicker market access for
new treatments.
Recent Development
- In April 2025, Abeona Therapeutics
announced that the U.S. Food and Drug Administration (FDA) approved ZEVASKYN
(reimagine zamikeracel), also known as pz-cel gene-modified cellular sheets, as
the first and only autologous cell-based gene therapy for treating wounds in
adult and pediatric patients with recessive dystrophic epidermolysis bullosa
(RDEB), a severe genetic skin disorder. With no existing cure for RDEB,
ZEVASKYN is the sole FDA-approved therapy offering wound treatment through a
single application.
- In April 2025, AGC Biologics launched a dedicated Cell
and Gene Business Division. Unlike other cell and gene CDMOs that are
downsizing and closing sites, AGC Biologics’ new Cell and Gene Technologies
Division provides exceptional scientific expertise and comprehensive support,
supported by a robust global development and manufacturing network spanning
three key regions: Milan, Italy; Longmont, Colorado, USA; and Yokohama, Japan.
- In February 2025, Enzo announced the launch of a new
line of small molecules tailored to drive innovation in the fast-evolving cell
therapy sector. These advanced molecules are designed to support diverse
research applications and therapeutic advancements, enhancing capabilities in
stem cell and gene therapy. Available in both RUO and GMP grades, they ensure
the highest standards of quality and consistency for therapeutic development.
Key Market Players
- Emmaus
International
- CellSeed
Inc.
- FUJIFILM
Holdings Corporation
- Japan
Tissue Engineering Co. Ltd.
|
By Sheet Type
|
By Application
|
By Country
|
- Monolayer Cell-sheet
- Co-culture Cell-sheet
- Multilayered Cell-sheet
- Others
|
- Oncology
- Ophthalmology
- Genetic Disorders
- Cardiology
- Others
|
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
|
Report Scope
In this report, the Asia Pacific Cell Sheet-based
Gene Therapy Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Asia Pacific Cell
Sheet-based Gene Therapy Market, By Sheet Type:
o Monolayer Cell-sheet
o Co-culture Cell-sheet
o Multilayered Cell-sheet
o Others
- Asia Pacific Cell
Sheet-based Gene Therapy Market, By Application:
o Oncology
o Ophthalmology
o Genetic Disorders
o Cardiology
o Others
- Asia Pacific Cell
Sheet-based Gene Therapy Market, By Country:
o China
o India
o Japan
o Australia
o South Korea
o Rest of Asia Pacific
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Asia Pacific Cell Sheet-based Gene Therapy Market.
Available Customizations:
Asia Pacific Cell Sheet-based Gene Therapy Market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Asia Pacific Cell
Sheet-based Gene Therapy Market is an upcoming report to be released soon. If
you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]